Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Protein Page:
BRCA1 (human)
p Phosphorylation
a Acetylation
m Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
u Ubiquitination
s Sumoylation
n Neddylation
g O-GlcNAc
h Palmitoylation
ad Adenylylation
sn S-Nitrosylation
ca Caspase cleavage

Overview
BRCA1 the BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Acts by mediating ubiquitin E3 ligase activity that is required for its tumor suppressor function. Plays a central role in DNA repair by facilitating cellular response to DNA repair. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACC1 and preventing its dephosphorylation. Defects in BRCA1 are a cause of genetic susceptibility to breast cancer. Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association may be a dynamic process changing throughout the cell cycle and within subnuclear domains. Interacts (via BRCT domains) with CTIP. Associates with RNA polymerase II holoenzyme. Interacts with SMC1 and COBRA1. Interacts (via BRCT domains) with BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with Artemis and claspin. Interacts with H2AFX (phosphorylated on S140). Interacts with CHK1. Interacts with BRCC3. Five human isoforms are produced by alternative splicing and alternative initiation. Isoform 1 and isoform 3 are widely expressed. Isoform 1 is largely nuclear, while isoforms 3 and 5 are cytoplasmic. Note: This description may include information from UniProtKB.
Protein type: EC 6.3.2.-; Nuclear receptor co-regulator; Ubiquitin conjugating system; Transcription, coactivator/corepressor; Ubiquitin ligase; Tumor suppressor
Cellular Component: nucleoplasm; filamentous actin; ruffle; gamma-tubulin ring complex; focal adhesion; protein complex; BRCA1-BARD1 complex; plasma membrane; chromosome; nucleus; ribonucleoprotein complex; ubiquitin ligase complex
Molecular Function: tubulin binding; identical protein binding; protein binding; enzyme binding; androgen receptor binding; DNA binding; zinc ion binding; RNA binding; ubiquitin protein ligase binding; transcription coactivator activity; ubiquitin-protein ligase activity
Biological Process: apoptosis; positive regulation of transcription, DNA-dependent; protein ubiquitination; positive regulation of histone H3-K4 methylation; chromosome segregation; regulation of apoptosis; DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; double-strand break repair; fatty acid biosynthetic process; negative regulation of fatty acid biosynthetic process; negative regulation of histone H3-K9 methylation; protein autoubiquitination; positive regulation of DNA repair; postreplication repair; DNA repair; cell cycle; negative regulation of centriole replication; double-strand break repair via homologous recombination; regulation of cell proliferation; regulation of transcription from RNA polymerase II promoter; DNA damage response, signal transduction resulting in induction of apoptosis; regulation of transcription from RNA polymerase III promoter; response to estrogen stimulus; positive regulation of protein ubiquitination; androgen receptor signaling pathway; positive regulation of histone acetylation; positive regulation of transcription from RNA polymerase II promoter; response to ionizing radiation; negative regulation of transcription, DNA-dependent; G2/M transition DNA damage checkpoint; response to DNA damage stimulus
Reference #:  P38398 (UniProtKB)
Alt. Names/Synonyms: BRCA1; BRCA1/BRCA2-containing complex, subunit 1; BRCAI; BRCC1; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein; breast cancer 1, early onset; Breast cancer type 1 susceptibility protein; BROVCA1; IRIS; PSCP; RING finger protein 53; RNF53
Gene Symbols: BRCA1
Molecular weight: 207,721 Da
Basal Isoelectric point: 5.29  Predict pI for various phosphorylation states
CST Pathways:  Cell Cycle: G2/M DNA Damage Checkpoint  |  Protein Acetylation
Protein-Specific Antibodies or siRNAs from Cell Signaling Technology® Total Proteins
Select Structure to View Below

BRCA1
Protein Structure Not Found.


STRING  |  Scansite  |  Phospho.ELM  |  NetworKIN  |  Pfam  |  RCSB PDB  |  Phospho3D  |  DISEASE  |  Source  |  NURSA  |  UCSD-Nature  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  Ensembl Gene


Sites Implicated In
cell cycle regulation: S1387‑p, S1423‑p, S1524‑p
transcription, altered: T509‑p, S632‑p
activation: S988‑p
intracellular localization: T509‑p, S988‑p, S1143‑p, S1189‑p, S1191‑p, S1280‑p, S1497‑p
molecular association, regulation: S1189‑p, S1423‑p, S1457‑p, S1497‑p, S1524‑p, S1542‑p
phosphorylation: S1423‑p, S1524‑p
protein stabilization: S694‑p

Modification Sites and Domains Show Modification Legend
Click here to view phosphorylation modifications only

Modification Sites in Parent Protein, Orthologs, and Isoforms Show Modification Legend
 

Show Multiple Sequence Alignment


 SS 

SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


  MS 

MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


        human

► Hide Isoforms 		 
0 1 K50-a FCKFCMLkLLNQKKG
0 4 S114-p FAKKENNsPEHLkDE
1 0 K119-s NNsPEHLkDEVsIIQ
0 1 S123-p EHLkDEVsIIQSMGY
0 1 T164-p SNLGTVRtLRTKQRI
0 1 S184 SVYIELGSDSSEDTV
0 1 S186 YIELGSDSSEDTVNK
0 1 S187 IELGSDSSEDTVNKA
0 6 T208-p DQELLQItPQGTRDE
1 0 S308-p KAEFCNKsKQPGLAR
0 5 S316 KQPGLARSQHNRWAG
0 5 S395-p RSDELLGsDDsHDGE
0 4 S398-p ELLGsDDsHDGESES
0 1 S423-p LNEVDEYsGSSEKID
0 1 S434-p EKIDLLAsDPHEALI
0 1 S451-p SERVHSKsVEsNIED
0 1 S454-p VHSKsVEsNIEDKIF
3 74 T509-p LKRKRRPtsGLHPED
0 6 S510-p KRKRRPtsGLHPEDF
0 1 G511 RKRRPtsGLHPEDFI
0 36 S615-p KNRLRRKsstRHIHA
0 36 S616-p NRLRRKsstRHIHAL
0 5 T617-p RLRRKsstRHIHALE
1 1 S632-p LVVSRNLsPPNCTEL
0 1 S643 CTELQIDSCSSsEEI
0 1 S647-p QIDSCSSsEEIKKKK
0 1 I650 SCSSsEEIKKKKYNQ
1 8 S694-p QTSKRHDsDTFPELK
0 1 S713 PGSFTKCSNTSELKE
0 4 N714 GSFTKCSNTSELKEF
0 2 L718 KCSNTSELKEFVNPS
0 3 S725 LKEFVNPSLPREEKE
0 1 S741-p KLETVKVsNNAEDPK
0 4 S753-p DPKDLMLsGERVLQT
0 6 S803-p TEPNKCVsQCAAFEN
0 2 S840 LGHEVNHSRETSIEM
0 1 S868 FKVSKRQSFAPFSNP
0 1 T967-p GNETGLItPNkHGLL
0 1 K970-u TGLItPNkHGLLQNP
0 1 Y978-p HGLLQNPyRIPPLFP
5 0 S988-p PPLFPIKsFVKTKCK
1 0 S1143-p PMGSSHAsQVCSETP
0 6 S1174 ENDIKESSAVFsKSV
0 1 S1178-p KESSAVFsKSVQKGE
0 5 S1180 SSAVFsKSVQKGELs
0 6 S1187-p SVQKGELsRsPsPFt
4 10 S1189-p QKGELsRsPsPFtHT
2 6 S1191-p GELsRsPsPFtHTHL
0 1 T1194-p sRsPsPFtHTHLAQG
0 4 S1211-p RGAKKLEssEENLss
0 3 S1212-p GAKKLEssEENLssE
0 6 S1217-p EssEENLssEDEELP
0 6 S1218-p ssEENLssEDEELPC
0 1 - gap
0 2 - gap
0 10 S1239-p GKVNNIPsQSTRHsT
0 2 S1245-p PsQSTRHsTVATECL
0 1 T1246 sQSTRHsTVATECLS
1 1 S1280-p QVILAKAsQEHHLsE
0 1 S1286-p AsQEHHLsEETKCSA
0 3 S1328-p SKQMRHQsEsQGVGL
0 3 S1330-p QMRHQsEsQGVGLsD
0 7 S1336-p EsQGVGLsDKELVsD
0 5 S1342-p LsDKELVsDDEERGT
6 0 S1387-p EDCSGLSsQSDILTT
11 2 S1423-p AVLEQHGsQPSNSYP
4 3 S1457-p SEKAVLTsQKsSEYP
0 3 S1460-p AVLTsQKsSEYPIsQ
0 4 S1466-p KsSEYPIsQNPEGLS
0 1 S1473 sQNPEGLSADKFEVS
0 1 S1483-p KFEVSADsSTSKNKE
5 4 S1497-p EPGVERSsPSKCPSL
0 2 C1501 ERSsPSKCPSLDDRW
8 7 S1524-p LQNRNYPsQEELIKV
1 2 S1542-p EEQQLEEsGPHDLTE
0 1 T1550-p GPHDLTEtSYLPRQD
1 0 S1572-p ESGISLFsDDPEsDP
0 1 S1577-p LFsDDPEsDPSEDRA
0 1 N1592 PESARVGNIPSSTSA
0 1 I1593 ESARVGNIPSSTSAL
0 1 S1598 GNIPSSTSALKVPQL
0 1 S1613-p KVAESAQsPAAAHTT
0 1 E1660 VVSGLTPEEFMLVYk
0 1 K1667 EEFMLVYKFARKHHI
0 1 K1667-u EEFMLVYkFARKHHI
0 1 K1671 LVYkFARKHHITLTN
0 1 T1700-p AEFVCERtLKYFLGI
0 1 T1720-p VVSYFWVtQSIKERK
0 1 S1722 SYFWVtQSIKERKML
0 1 T1777-p GPFTNMPtDQLEWMV
0 1 S1790-p MVQLCGAsVVKELSS
9009 : Phospho-BRCA1 (Ser1524) Antibody
  BRCA1 iso6  
K50 FCKFCMLKLLNQKKG
S114 FAKKENNSPEHLKDE
K119 NNSPEHLKDEVSIIQ
S123 EHLKDEVSIIQSMGY
T164 SNLGTVRTLRTKQRI
S184 SVYIELGSDSSEDTV
S186 YIELGSDSSEDTVNK
S187 IELGSDSSEDTVNKA
T208 DQELLQITPQGTRDE
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
- gap
S284 EDCSGLSSQSDILTT
S320 AVLEQHGSQPSNSYP
S353 TSEKVLTSQKsSEYP
S356-p KVLTSQKsSEYPIsQ
S362-p KsSEYPIsQNPEGLs
S369-p sQNPEGLsADKFEVS
S379 KFEVSADSSTSKNKE
S393 EPGVERSSPSKCPSL
C397 ERSSPSKCPSLDDRW
S420 LQNRNYPSQEELIKV
S438 EEQQLEESGPHDLTE
T446 GPHDLTETSYLPRQD
S468 ESGISLFSDDPESDP
S473 LFSDDPESDPSEDRA
N488 PESARVGNIPSSTSA
I489 ESARVGNIPSSTSAL
S494 GNIPSSTSALKVPQL
S509 KVAESAQSPAAAHTT
E556 VVSGLTPEEFMLVYK
K563 EEFMLVYKFARKHHI
K563 EEFMLVYKFARKHHI
K567 LVYKFARKHHITLTN
T596 AEFVCERTLKYFLGI
T616 VVSYFWVTQSIKERK
S618 SYFWVTQSIKERKML
T673 GPFTNMPTGCPPNCG
- gap
  mouse

 
K50 FCKFCMLKLLNQKKG
S114-p FSKKRNNsCERLNEE
N119 NNsCERLNEEASIIQ
S123 ERLNEEASIIQSVGY
S163 SNLGIVRSVKKNRQT
S183-p SVYIELDsDssEETV
S185-p YIELDsDssEETVTK
S186-p IELDsDssEETVTKP
A207 DQELLQTAPQEAGDE
S305 KAEFCNKSKQPGIAV
S313-p KQPGIAVsQQSRWAA
S392 RTGEMLTSDSASARR
A395 EMLTSDSASARRHES
F420 SNEVDGGFSSSRKTD
P431 RKTDLVTPDPHHTLM
P448 SGRDFSKPVEDNISD
D451 DFSKPVEDNISDKIF
S502-p NKLKRKRsTsLQPED
T503 KLKRKRsTsLQPEDF
S504-p LKRKRsTsLQPEDFI
S609 KNRLRRKSSIRCALP
S610 NRLRRKSSIRCALPL
I611 RLRRKSSIRCALPLE
S625-p EPISRNPsPPTCAEL
S636-p CAELQIDsCGSSEEt
S640 QIDsCGSSEEtKKNH
T643-p sCGSSEEtKKNHSNQ
S686-p HIRKRRAsDAFPEEK
S705-p AGLLTSCssPRKsQG
S706-p GLLTSCssPRKsQGP
S710-p SCssPRKsQGPVNPs
S717-p sQGPVNPsPQRTGTE
S732 QLETRQMSDSAKELG
G744 ELGDRVLGGEPSGKT
T795 TGSAQCMTQFVASEN
S831-p LRHALNLsQEKVEME
S858-p FQVSKRQsFALFSKP
A950 SGENGLSATGKSGIS
K953 NGLSATGKSGISQNS
H961 SGISQNSHFKQSVSP
S971-p QSVSPIRsSIKTDNR
F1106 QSMSGKVFQVCSETP
S1137-p EGDIMERsAVFNGsI
N1141 MERsAVFNGsILRRE
S1143-p RsAVFNGsILRRESs
S1150-p sILRRESsRsPsPVT
S1152-p LRRESsRsPsPVTHA
S1154-p RESsRsPsPVTHASK
T1157 sRsPsPVTHASKSQS
S1174 RASRKLESSEESDST
S1175 ASRKLESSEESDSTE
S1180 ESSEESDSTEDEDLP
T1181 SSEESDSTEDEDLPC
S1197-p QHLLSRIsNtPELTR
T1199-p LLSRIsNtPELTRCS
- gap
S1206 tPELTRCSsAVTQRM
S1207-p PELTRCSsAVTQRMP
S1241 EVIMIEASQEHQFSE
S1247 ASQEHQFSEDPRCSG
C1289 SKQRSHQCGNEEAFL
N1291 QRSHQCGNEEAFLSD
S1297 GNEEAFLSDKELISD
S1303 LSDKELISDNEEMAT
S1343 TNLSEDCSQSDILTT
N1379 AVLEQRGNQPSGHSP
S1413 SGAAILTSKNINENP
I1416 AILTSKNINENPVsQ
S1422-p NINENPVsQNLKSAC
C1429 sQNLKSACDDKFQLQ
G1440 FQLQHLEGPTSGDDE
S1454-p ESGMGRPsPFKsPLA
S1458-p GRPsPFKsPLAGSRG
S1481 LQKRNSPSQEELLQP
S1495 PAGSEASSEPHNSTG
Q1503 EPHNSTGQSCLPRRE
S1525 GSGISLFSSRDPESE
R1527 GISLFSSRDPESESP
T1542-p KEPAHIGttPASTsA
T1543-p EPAHIGttPASTsAL
S1548-p GttPASTsALKIPQG
S1561 QGQVAFRSAAAAGAD
K1603-a VVSGLTPkEVMTVQk
K1610-a kEVMTVQkFAEkYRL
K1610 kEVMTVQKFAEkYRL
K1614-a TVQkFAEkYRLTLTD
T1643 AEFVCERTLKYFLGI
V1663 IVSYSWVVRsIQERR
S1665-p SYSWVVRsIQERRLL
K1719 EPFTNMPKDELERML
S1732 MLQLCGASVVKELPS
  rat

 
K50 FCKFCMLKLLNQKKG
S114 FSKKKNSSSELLNED
N119 NSSSELLNEDASIIQ
S123 ELLNEDASIIQSVGY
S163 SNLGIVRSMKKNRQT
S183 SVYIALESDSSEERV
S185 YIALESDSSEERVNA
S186 IALESDSSEERVNAP
A207 DQELFQIAPGGAGDE
S306 KAEFCDRSKQSGAAV
S314 KQSGAAVSQQSRWAD
S393 RTGEMLTSDNASDRR
A396 EMLTSDNASDRRPAS
F421 SNEVDGCFSSSKKID
P432 KKIDLVAPDPDNAVM
P449 SGRDFSKPVENIIND
N452 DFSKPVENIINDKIF
S503 NKLKRKRSTCLHPED
T504 KLKRKRSTCLHPEDF
C505 LKRKRSTCLHPEDFI
S610 KNRLRRKSTRCVLPL
T611 NRLRRKSTRCVLPLE
- gap
S625 EPISRNPSPPTCAEL
S636 CAELQIESCGSSEET
S640 QIESCGSSEETKKNN
T643 SCGSSEETKKNNSNQ
S686 HIRKRSASDAFPEEK
S705 AGLLTSCSSPRKPQG
S706 GLLTSCSSPRKPQGP
P710 SCSSPRKPQGPVNPS
S717 PQGPVNPSPERKGIE
P732 QLEMCQMPDNNKELG
G744 ELGDLVLGGEPSGKP
T795 TGSVQCMTQFVASEN
N831 LRHELNHNQETIEME
S858 FQVSKRQSFALFSKL
T954 SCENGLNTTDKSGIS
K957 NGLNTTDKSGISQNS
H965 SGISQNSHFRQSVSP
S975 QSVSPLRSSIKTDNR
F1107 PMRSDKTFQVCSETP
S1138 EGGITEKSAIFNGSV
N1142 TEKSAIFNGSVLRRE
S1144 KSAIFNGSVLRRESS
S1151 SVLRRESSRSPSPVT
S1153 LRRESSRSPSPVTHA
S1155 RESSRSPSPVTHASK
T1158 SRSPSPVTHASKSRS
F1175 RGSRKLEFSEESDST
S1176 GSRKLEFSEESDSTE
S1181 EFSEESDSTEDEDLP
T1182 FSEESDSTEDEDLPC
S1198 QHLLSRVSSTPELTR
T1200 LLSRVSSTPELTRCS
- gap
S1207 TPELTRCSSVVTQRV
S1208 PELTRCSSVVTQRVP
S1242 EVILGEASQEYQFSE
S1248 ASQEYQFSEDAKCSG
A1290 SKQRRHQAENEEAFL
N1292 QRRHQAENEEAFLSD
S1298 ENEEAFLSDKELISD
S1304 LSDKELISDHEDMAA
S1344 ANLSEDCSQSDILTT
S1380 AVLEQHGSQPSGHPP
S1414 SGTAILTSKNINENP
I1417 AILTSKNINENPVSQ
S1423 NINENPVSQNPKRAC
C1430 SQNPKRACDDKSQPQ
G1441 SQPQPPDGLPSGDKE
S1455 ESGMRRPSPFKSPLT
S1459 RRPSPFKSPLTSSRC
S1482 LQNRNSTSQEELLQP
C1496 PAXLEKSCEPHNLTG
R1504 EPHNLTGRSCLPRQD
S1526 ESGIRLVSSRDPDSE
R1528 GIRLVSSRDPDSESP
T1543 KVSALVCTAPASTSA
A1544 VSALVCTAPASTSAL
S1549 CTAPASTSALKISQG
S1564 QVAGSCRSPAAGGAD
K1606 VVSGLTPKEVMIVQK
K1613 KEVMIVQKFAEKYRL
K1613 KEVMIVQKFAEKYRL
K1617 IVQKFAEKYRLALTD
T1646 AEFVCERTLKYFLGI
I1666 IVSYSWVIKSIQERK
S1668 SYSWVIKSIQERKLL
K1722 EPFTNMPKDELERML
S1735 MLQLCGASVVKELPL
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.